Respiratory microbiome in IPF: Cause, effect, or biomarker?

The Lancet Respiratory Medicine

Volumn 2, Issue 7, 2014, Pages 511-513

  Molyneaux, Philip L ^a,b   Maher, Toby M ^a,b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; RNA 16S; BACTERIAL DNA;

DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; ENVIRONMENTAL EXPOSURE; ESCHERICHIA; EXTRACELLULAR MATRIX; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNE RESPONSE; LUNG ALVEOLUS EPITHELIUM; MICROBIOME; NONHUMAN; NOTE; PATHOGENESIS; PHYLOGENY; PREVOTELLA; PRIORITY JOURNAL; STAPHYLOCOCCUS; STREPTOCOCCUS; VEILLONELLA; FEMALE; ISOLATION AND PURIFICATION; LUNG; MALE; MICROBIOLOGY; MICROFLORA;

DNA, BACTERIAL; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; MALE; MICROBIOTA; STAPHYLOCOCCUS; STREPTOCOCCUS;

EID: 84903996446     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(14)70088-8     Document Type: Note

References (11)

1. Maher TM, Wells AU, Laurent GJ Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?. Eur Respir J 2007, 30:835-839.
2. Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 2011, 364:1503-1512.
3. Fingerlin TE, Murphy E, Zhang W, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet 2013, 45:613-620.
4. Molyneaux PL, Maher TM The role of infection in the pathogenesis of idiopathic pulmonary fibrosis. Eur Respir Rev 2013, 22:376-381.
5. Huang YJ, Charlson ES, Collman RG, Colombini-Hatch S, Martinez FD, Senior RM The role of the lung microbiome in health and disease: A National Heart, Lung and Blood Institute Workshop Report. Am J Respir Crit Care Med 2013, 187:1382-1387.
6. Hilty M, Burke C, Pedro H, et al. Disordered microbial communities in asthmatic airways. PLoS One 2010, 5:e8578.
7. Molyneaux PL, Mallia P, Cox MJ, et al. Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013, 188:1224-1231.
8. Erb-Downward JR, Thompson DL, Han MK, et al. Analysis of the lung microbiome in the "healthy" smoker and in COPD. PLoS One 2011, 6:e16384.
9. Zhao J, Schloss PD, Kalikin LM, et al. Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci USA 2012, 109:5809-5814.
10. Han MK, Zhou Y, Murray S, et al. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respir Med 2014, for the COMET Investigators, published online April 22. http://dx.doi.org/10.1016/S2213-2600(14)70069-4.
11. Shulgina L, Cahn AP, Chilvers ER, et al. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial. Thorax 2013, 68:155-162.